Nektar Therapeutics NKTR Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Nektar Therapeutics's net gains (losses) on investments?
- Nektar Therapeutics (NKTR) reported net gains (losses) on investments of -$1.75M in Q1 2026.
- How has Nektar Therapeutics's net gains (losses) on investments changed year-over-year?
- Nektar Therapeutics's net gains (losses) on investments increased by 60.8% year-over-year, from -$4.46M to -$1.75M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.